Pimecrolimus
| Evidence Level: L2 | Predicted Indications: 4 |
Table of Contents
Pimecrolimus: From Atopic Dermatitis to Seborrheic Dermatitis
One-Sentence Summary
Pimecrolimus is a topical calcineurin inhibitor cream, originally used to treat atopic dermatitis (eczema). The TxGNN model predicts it may be effective for seborrheic dermatitis, with 1 clinical trial (a completed Phase 2 randomized study) and 18 publications (including two systematic reviews of randomized trials) currently supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Atopic dermatitis (atopic eczema) |
| Predicted New Indication | Seborrheic dermatitis |
| TxGNN Prediction Score | 99.73% |
| Evidence Level | L2 |
| US Market Status | Cancelled only (all 3 authorizations cancelled) |
| Number of NDAs | 3 (1 NDA and 2 ANDAs) |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for pimecrolimus are not available in the data compiled for this report. The literature does describe it as a calcineurin inhibitor that selectively targets T cells and mast cells. It inhibits T-cell proliferation and the production of IL-2, IL-4, interferon-gamma and TNF-alpha, and it also inhibits mast cell degranulation.
Atopic dermatitis is a T-cell-driven inflammatory skin disease, and pimecrolimus is established as a non-steroidal treatment for it. Seborrheic dermatitis is a chronic, relapsing inflammatory skin condition affecting sebum-rich areas, and it is linked to an inflammatory response to Malassezia yeast. Topical anti-inflammatory immunomodulation is therefore mechanistically plausible, and the two diseases share an inflammatory pathway. Reviews note that corticosteroids have limited long-term use in seborrheic dermatitis because of adverse effects, and that topical calcineurin inhibitors are a proposed alternative.
This mechanistic link is inferred from the known drug class rather than from drug-specific mechanism data.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00403559 | Phase 2 | Completed | 113 | 4-week randomized, double-blind, parallel-group, active-comparator study of Elidel (pimecrolimus) in seborrheic dermatitis. It was designed as an exploratory study of effectiveness, and no results are summarized in the data compiled. |
This is the only registered trial directly in seborrheic dermatitis. It is Phase 2 rather than Phase 3, so it supports Evidence Level L2 rather than L1.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 22142161 | 2012 | Systematic review of RCTs | Expert Rev Clin Pharmacol | Evaluated pimecrolimus 1% cream against corticosteroids, antimycotics, placebo or no intervention. It appears well tolerated and effective, with efficacy comparable to the comparators. |
| 36072203 | 2022 | Systematic review of RCTs | Cureus | Critical review of the efficacy and safety of pimecrolimus in facial seborrheic dermatitis. |
| 27804089 | 2017 | Systematic review | Am J Clin Dermatol | Reviews topical treatments for facial seborrheic dermatitis. Calcineurin inhibitors are not among the three agent categories named in the abstract (antifungals, keratolytics, corticosteroids). |
| 19222250 | 2009 | Review | Am J Clin Dermatol | Reviews topical calcineurin inhibitors in seborrheic dermatitis. They are presented as a safer alternative to corticosteroids, which have limited use because of long-term adverse effects. |
| 31053034 | 2019 | Review (off-label uses) | J Cutan Med Surg | Reviews off-label uses of topical pimecrolimus, focusing on published RCTs. |
| 20000875 | 2010 | Open-label study | Am J Clin Dermatol | Pimecrolimus 1% cream for resistant facial seborrheic dermatitis. It was reported as effective and well tolerated. |
| 17982237 | 2007 | Open-label study | J Korean Med Sci | 20 Korean patients applied pimecrolimus 1% cream for 4 weeks for facial seborrheic dermatitis, to assess efficacy and tolerability. |
| 16033622 | 2005 | Review | Int J Clin Pract | Describes pimecrolimus as targeting T cells and mast cells, and discusses uses beyond atopic dermatitis. |
| 17020422 | 2006 | Review | Expert Opin Pharmacother | Pimecrolimus is approved for atopic dermatitis and is described as having great potential in other inflammatory skin diseases. |
| 20347654 | 2010 | Review (safety signal) | Clin Dermatol | Tinea incognito can arise after topical corticosteroids or immunomodulators such as pimecrolimus. It can mimic seborrheic dermatitis, so diagnosis is often missed or delayed. |
Several other retrieved publications were only tangentially related and are not listed.
US Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| NDA021302 | Pimecrolimus (Oceanside Pharmaceuticals) | Cream | Not listed (status: cancelled) |
| ANDA209345 | Pimecrolimus (Actavis Pharma, Inc.) | Cream | Not listed (status: cancelled) |
| ANDA211769 | Pimecrolimus (Glenmark Pharmaceuticals Inc., USA) | Cream | Not listed (status: cancelled) |
All three authorizations are single-ingredient topical creams and all are cancelled, so no currently valid US authorization appears in the data compiled.
Safety Considerations
- Boxed warning (from the evaluation of this candidate): The label carries a boxed warning on long-term use because of a theoretical malignancy risk. The text of the package insert itself was not available, so this should be verified against the current label.
- Contraindication signals from the knowledge graph (not label text): The graph links pimecrolimus with the following conditions. Most are viral infections or related skin conditions, which fits an immunomodulating agent that could worsen infections.
- Common wart
- Epidermodysplasia verruciformis
- Anogenital human papillomavirus infection
- Herpes simplex infectious disease
- Herpes simplex dermatitis
- Herpes zoster
- Chickenpox
- Infectious mononucleosis
- Chronic Epstein-Barr virus infection syndrome
- Lymphatic system disease
- Netherton syndrome
- Ichthyosis linearis circumflexa
- Drug interactions: The interaction screen returned 100 potential interacting drugs, none with a severity level assigned. Examples include prednisone, hydrocortisone, triamcinolone, budesonide, omeprazole, pantoprazole, metformin, simvastatin, doxycycline and metronidazole. Systemic exposure from topical use is low, so the practical relevance is likely limited.
- Diagnostic caution: Immunomodulator use can mask or worsen dermatophyte infection (tinea incognito), which can resemble seborrheic dermatitis.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: A completed, randomized Phase 2 trial in seborrheic dermatitis plus two systematic reviews of RCTs and several open-label studies support effectiveness and tolerability. The evidence is below Phase 3 level, the boxed warning on long-term use applies, and all US authorizations are currently cancelled, so this is not a straightforward Go.
To proceed, the following is needed:
- Review of the current package insert (warnings, contraindications, boxed warning text), as label safety data are not available in the data compiled
- Results from NCT00403559 and, ideally, a Phase 3 randomized trial in seborrheic dermatitis
- Drug-specific mechanism of action data to replace the class-based inference
- A regulatory and availability plan, since no US authorization is currently valid
- A safety plan covering limits on duration of use, infection screening (viral and fungal), and avoidance in infants under 2 years
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.